Amid an uptick in COVID-19 hospitalizations, vaccine makers say the updated shots they’ve developed for fall are proving effective against the newer variants that are now circulating widely.
Moderna Inc. MRNA, -4.35%, meanwhile, said Thursday that preliminary clinical-trial data show that its updated COVID-19 shot significantly boosted neutralizing antibodies against EG.5 as well as the Fornax FL 1.5.1 variant that is starting to surge in parts of the U.S. The EG.5 variant, which has shown increased prevalence and immune-escape properties, may cause a rise in cases and potentially become dominant globally, the World Health Organization said in a report last week.